Related Experiment Video
Updated: Jan 2, 2026
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical
Pichaya Thanindratarn1, Dylan C Dean2, Scott D Nelson3
1Department of Orthopedic Surgery, Sarcoma Biology Laboratory, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Department of Orthopedic Surgery, Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand.
Abstract:
Survival rates for sarcoma patients have plateaued in the past few decades and remain especially grim for those with recurrent or metastatic disease. This has prompted investigation into novel immunotherapies for sarcomas, especially after their recent and well-recognized successes in other cancers. One such modality, the Chimeric Antigen Receptor (CAR) T Cell therapy, has shown promising results in treating B-cell lymphoma and acute lymphoblastic leukemia. This novel therapy functions by fusing a specific antibody derived single-chain variable fragment (scFv) with a T-cell which recognizes a specific tumor-associated antigen (TAA). Several sarcoma-associated antigens (SAA) amenable to CAR-T cell treatment have recently emerged with encouraging results. These include human epidermal growth factor receptor 2 (HER2), disialoganglioside (GD2), interleukin 11 Receptor Subunit Alpha (IL-11RA), fibroblast activation protein (FAP), B7-H3, CD44v6, insulin-like growth factor 1 receptor (IGF-1R), and tyrosine kinase orphan-like receptor 1 (ROR1). Given the limitations of current medical therapies, novel treatment strategies are urgently needed. As a sarcoma treatment modality, CAR-T cell therapy is highly promising and continues to draw interest especially as new clinical trials emerge. Here we review recent breakthrough CAR-T cell studies in sarcoma, the targets which define them, and approaches to minimizing host cytotoxicity.
Insights
Chimeric Antigen Receptor (CAR) T-cell therapy shows promise for sarcoma treatment, targeting specific antigens like HER2 and GD2. Research is exploring novel approaches to improve efficacy and minimize side effects for recurrent or metastatic disease.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Sarcoma survival rates have stagnated, particularly for recurrent or metastatic cases.
- Chimeric Antigen Receptor (CAR) T-cell therapy has proven effective in other cancers like lymphoma and leukemia.
- Novel immunotherapies are crucial given the limitations of current sarcoma treatments.
Purpose of the Study:
- To review recent advancements in CAR T-cell therapy for sarcoma.
- To identify key sarcoma-associated antigens (SAAs) targeted by CAR T-cells.
- To discuss strategies for mitigating host anti-tumor responses and improving safety.
Main Methods:
- Review of recent CAR T-cell studies in sarcoma.
- Identification and analysis of various sarcoma-associated antigens (SAAs) for CAR T-cell targeting.
- Exploration of methods to minimize on-target, off-tumor toxicities.
Main Results:
- Several SAAs, including HER2, GD2, IL-11RA, FAP, B7-H3, CD44v6, IGF-1R, and ROR1, show potential for CAR T-cell therapy in sarcoma.
- CAR T-cell therapy demonstrates encouraging preliminary results in preclinical and early clinical studies for sarcoma.
- Strategies for managing potential toxicities are being developed.
Conclusions:
- CAR T-cell therapy represents a highly promising novel treatment modality for sarcoma.
- Targeting specific SAAs is key to effective CAR T-cell therapy in sarcoma.
- Ongoing research focuses on optimizing CAR T-cell therapy to improve patient outcomes and safety profiles.
